MedTrace Logo

Stereotactic Ablative Radiotherapy for Early-stage Glottic Larynx Cancer

NCT03548285 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-05-22

Study results available
· View outcomes & findings →

Summary

This is a prospective study to determine the local control and quality-of-life outcomes of using SBRT for early-stage glottic larynx cancer.

Conditions

  • Glottic Carcinoma

Interventions

RADIATION

Radiation therapy

Stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiation therapy (SBRT)

Sponsors & Collaborators

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • David Sher, MD · University of Texas Southwestern Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-15
Primary Completion
2023-04-25
Completion
2024-04-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03548285 on ClinicalTrials.gov